[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 167,451
  • Shares Outstanding, K 14,423
  • Annual Sales, $ 6,390 K
  • Annual Income, $ -117,260 K
  • EBIT $ -87 M
  • EBITDA $ -84 M
  • 60-Month Beta 3.07
  • Price/Sales 25.27
  • Price/Cash Flow N/A
  • Price/Book 1.35

Options Overview Details

View History
  • Implied Volatility 81.22% (-44.38%)
  • Historical Volatility 79.84%
  • IV Percentile 4%
  • IV Rank 4.33%
  • IV High 316.82% on 02/13/26
  • IV Low 70.56% on 12/11/25
  • Expected Move (DTE 25) 1.73 (14.86%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 210
  • Volume Avg (30-Day) 80
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 2,256
  • Open Int (30-Day) 2,608
  • Expected Range 9.88 to 13.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.43
  • Number of Estimates 5
  • High Estimate $-0.66
  • Low Estimate $-1.77
  • Prior Year $-2.74
  • Growth Rate Est. (year over year) +47.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.12 +27.30%
on 05/20/26
14.14 -17.89%
on 04/23/26
-2.38 (-17.01%)
since 04/22/26
3-Month
9.12 +27.30%
on 05/20/26
15.56 -25.36%
on 04/06/26
+0.50 (+4.50%)
since 02/20/26
52-Week
5.20 +123.08%
on 12/02/25
55.89 -79.23%
on 10/16/25
-3.20 (-21.61%)
since 05/22/25

Most Recent Stories

More News
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1...

KRRO : 11.61 (+3.66%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform...

KRRO : 11.61 (+3.66%)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update

Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy...

KRRO : 11.61 (+3.66%)
Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to...

KRRO : 11.61 (+3.66%)
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences

American Society of Gene and Cell Therapy 29 th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference 3 rd International Conference on Ureagenesis Defects...

KRRO : 11.61 (+3.66%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...

KRRO : 11.61 (+3.66%)
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?

Insiders aggressively bought these stocks, signaling confidence in their operations. The question is whether others think the same.

SSP : 3.42 (-2.01%)
SVC : 1.7100 (-0.58%)
WRB : 67.54 (+0.10%)
KRRO : 11.61 (+3.66%)
CPNG : 16.12 (+2.48%)
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1...

KRRO : 11.61 (+3.66%)
Korro Announces Oversubscribed $85 Million Private Placement

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA...

KRRO : 11.61 (+3.66%)
Korro to Present at the TD Cowen 46th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly...

KRRO : 11.61 (+3.66%)

Business Summary

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 13.02
2nd Resistance Point 12.60
1st Resistance Point 12.10
Last Price 11.61
1st Support Level 11.18
2nd Support Level 10.76
3rd Support Level 10.26

See More

52-Week High 55.89
Fibonacci 61.8% 36.53
Fibonacci 50% 30.55
Fibonacci 38.2% 24.57
Last Price 11.61
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.